Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-blind randomized trial of early lung ultrasound-guided surfactant in premature infants with RDS
2024-515641-42-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Intubation rate within 72 hours of life. Planned start Jun 2024; status: authorised.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2024-515641-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515641-42-00.